Advertisement
U.S. Markets open in 6 hrs 57 mins

Recce Pharmaceuticals Ltd (RECEF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed Price. Currency in USD
0.60000.0000 (0.00%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0000
Open0.5500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.6000 - 0.6000
52 Week Range0.4610 - 0.6000
Volume1,000
Avg. Volume0
Market Cap139.123M
Beta (5Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateAug 30, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

    Phase II trial assessing the efficacy of RECCE® 327 topical gel (R327G) against acute bacterial skin and skin structure infectionsR327G demonstrating promising antibacterial effect across a broad range of human infectionsClinical study review board on track for mid-October, with interim results to followTrial study locations expand across New South Wales (NSW) and Victoria, broadening access to this potentially novel approach SYDNEY, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd.,

  • GlobeNewswire

    Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan

    A$4.4 million of valid applications received for the Share Purchase PlanIn conjunction with recently completed A$8.0 million institutional placement, total amount raised is A$12.4 millionProceeds will be used to advance clinical trials for intravenous use of R327, topical applications of R327G, including Phase III clinical activities in Indonesia, and IND-enabling activitiesPro forma cash position of A$19.8 million SYDNEY, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FS